Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2019

01-06-2019 | Liver Transplantation | Original Article

Pre-transplant ALBI Grade 3 Is Associated with Increased Mortality After Liver Transplantation

Authors: Nicole Bernardi, Marcio F. Chedid, Tomaz J. M. Grezzana-Filho, Aljamir D. Chedid, Marcelo A. Pinto, Ian Leipnitz, João E. Prediger, Carolina Prediger, Ariane N. Backes, Thais O. Hammes, Lea T. Guerra, Alexandre de Araujo, Mario R. Alvares-da-Silva, Cleber R. P. Kruel

Published in: Digestive Diseases and Sciences | Issue 6/2019

Login to get access

Abstract

Background

Although MELD score is a reliable tool for estimating mortality in the waiting list, criteria for preoperative prediction of survival after liver transplantation (LT) are lacking. ALBI score was validated as a prognostic marker for hepatocellular carcinoma patients undergoing transarterial chemoembolization, hepatic resection, and sorafenib treatment but not for LT outcomes yet. This study aimed to evaluate ALBI score as a prognostic factor in LT.

Methods

This is a single-center analysis of patients undergoing LT between October 2001 and June 2017. Primary endpoint was overall post-LT mortality. Secondary endpoint was 90-day mortality.

Results

Of all 301 patients included in this study, 185 (61.5%) were males. The median age was 54.1 ± 11.3 years. Univariate and multivariate analysis revealed that ALBI grade 3 (HR 1.836, 95% CI 1.154–2.921, p = 0.010), low serum albumin (HR 0.628, 95% CI 0.441–0.893, p = 0.010), black race (HR 2.431, 95% CI 1.160–5.092, p = 0.019), and elevated body mass index (HR 1.061, 95% CI 1.022–1.102, p = 0.002) all were associated with decreased overall survival following LT. Patients with both ALBI grade 3 (n = 25) and calculated MELD score ≥ 25 had the lowest overall survival (p < 0.001).

Discussion

ALBI grade 3 was related to lower post-LT survival and can be utilized as a tool for risk stratification in LT.
Literature
1.
go back to reference Chen HP, Tsai YF, Lin JR, Liu FC, Yu HP. Recipient age and mortality risk after liver transplantation: a population-based cohort study. PLoS ONE. 2016;11:e0152324.CrossRefPubMedPubMedCentral Chen HP, Tsai YF, Lin JR, Liu FC, Yu HP. Recipient age and mortality risk after liver transplantation: a population-based cohort study. PLoS ONE. 2016;11:e0152324.CrossRefPubMedPubMedCentral
2.
go back to reference Rana A, Ackah RL, Webb GJ, et al. No gains in long-term survival after liver transplantation over the past three decades. Ann Surg. 2019;269:20–27.CrossRefPubMed Rana A, Ackah RL, Webb GJ, et al. No gains in long-term survival after liver transplantation over the past three decades. Ann Surg. 2019;269:20–27.CrossRefPubMed
3.
go back to reference Alferink LJM, Oey RC, Hansen BE, et al. The impact of infections on delisting patients from the liver transplantation waiting list. Transpl Int. 2017;30:807–816.CrossRefPubMed Alferink LJM, Oey RC, Hansen BE, et al. The impact of infections on delisting patients from the liver transplantation waiting list. Transpl Int. 2017;30:807–816.CrossRefPubMed
4.
go back to reference Kalafateli M, Mantzoukis K, Choi Yau Y, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. J Cachexia Sarcopenia Muscle. 2017;8:113–121.CrossRefPubMed Kalafateli M, Mantzoukis K, Choi Yau Y, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. J Cachexia Sarcopenia Muscle. 2017;8:113–121.CrossRefPubMed
5.
go back to reference Huo TI, Lin HC, Lee SD. Model for end-stage liver disease and organ allocation in liver transplantation: where are we and where should we go? J Chin Med Assoc. 2006;69:193–198.CrossRefPubMed Huo TI, Lin HC, Lee SD. Model for end-stage liver disease and organ allocation in liver transplantation: where are we and where should we go? J Chin Med Assoc. 2006;69:193–198.CrossRefPubMed
6.
go back to reference Ling Q, Dai H, Zhuang R, et al. Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry. Sci Rep. 2017;7:42253.CrossRefPubMedPubMedCentral Ling Q, Dai H, Zhuang R, et al. Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry. Sci Rep. 2017;7:42253.CrossRefPubMedPubMedCentral
7.
go back to reference Klein KB, Stafinski TD, Menon D. Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature. PLoS ONE. 2013;8:e80661.CrossRefPubMedPubMedCentral Klein KB, Stafinski TD, Menon D. Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature. PLoS ONE. 2013;8:e80661.CrossRefPubMedPubMedCentral
8.
go back to reference Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl. 2017;23:1451–1464.CrossRefPubMed Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl. 2017;23:1451–1464.CrossRefPubMed
10.
go back to reference Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66:338–346.CrossRefPubMed Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66:338–346.CrossRefPubMed
11.
go back to reference Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33:550–558.CrossRefPubMed Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33:550–558.CrossRefPubMed
12.
go back to reference Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transpl. 2005;5:307–313.CrossRef Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transpl. 2005;5:307–313.CrossRef
13.
go back to reference Freeman RB. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology. 2008;47:1052–1057.CrossRefPubMed Freeman RB. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology. 2008;47:1052–1057.CrossRefPubMed
14.
go back to reference Onaca NN, Levy MF, Netto GJ, et al. Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transpl. 2003;3:626–630.CrossRef Onaca NN, Levy MF, Netto GJ, et al. Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transpl. 2003;3:626–630.CrossRef
15.
go back to reference Ioannou GN. Development and validation of a model predicting graft survival after liver transplantation. Liver Transpl. 2006;12:1594–1606.CrossRefPubMed Ioannou GN. Development and validation of a model predicting graft survival after liver transplantation. Liver Transpl. 2006;12:1594–1606.CrossRefPubMed
16.
go back to reference Dutkowski P, Oberkofler CE, Slankamenac K, et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg. 2011;254:745–753.CrossRefPubMed Dutkowski P, Oberkofler CE, Slankamenac K, et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg. 2011;254:745–753.CrossRefPubMed
17.
go back to reference Halldorson JB, Bakthavatsalam R, Fix O, Reyes JD, Perkins JD. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transpl. 2009;9:318–326.CrossRef Halldorson JB, Bakthavatsalam R, Fix O, Reyes JD, Perkins JD. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transpl. 2009;9:318–326.CrossRef
18.
go back to reference Hiraoka A, Kumada T, Kudo M, et al. Albumin–bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child–Pugh classifications. Liver Cancer. 2017;6:204–215.CrossRefPubMedPubMedCentral Hiraoka A, Kumada T, Kudo M, et al. Albumin–bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child–Pugh classifications. Liver Cancer. 2017;6:204–215.CrossRefPubMedPubMedCentral
19.
go back to reference Wang YY, Zhong JH, Su ZY, et al. Albumin–bilirubin versus Child–Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016;103:725–734.CrossRefPubMed Wang YY, Zhong JH, Su ZY, et al. Albumin–bilirubin versus Child–Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016;103:725–734.CrossRefPubMed
20.
go back to reference Zou H, Wen Y, Yuan K, et al. Combining albumin–bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. Liver Int. 2018;38:494–502.CrossRefPubMed Zou H, Wen Y, Yuan K, et al. Combining albumin–bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. Liver Int. 2018;38:494–502.CrossRefPubMed
21.
go back to reference Andreatos N, Amini N, Gani F, et al. Albumin–bilirubin score: predicting short-term outcomes including bile leak and post-hepatectomy liver failure following hepatic resection. J Gastrointest Surg. 2017;21:238–248.CrossRefPubMed Andreatos N, Amini N, Gani F, et al. Albumin–bilirubin score: predicting short-term outcomes including bile leak and post-hepatectomy liver failure following hepatic resection. J Gastrointest Surg. 2017;21:238–248.CrossRefPubMed
22.
23.
go back to reference Kanda M, Tanaka C, Kobayashi D, et al. Preoperative albumin–bilirubin grade predicts recurrences after radical gastrectomy in patients with pT2-4 gastric cancer. World J Surg. 2017;42:773–781.CrossRef Kanda M, Tanaka C, Kobayashi D, et al. Preoperative albumin–bilirubin grade predicts recurrences after radical gastrectomy in patients with pT2-4 gastric cancer. World J Surg. 2017;42:773–781.CrossRef
24.
go back to reference Ronald J, Wang Q, Choi SS, et al. Albumin–bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation. Diagn Interv Imaging. 2018;99:163–168.CrossRefPubMed Ronald J, Wang Q, Choi SS, et al. Albumin–bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation. Diagn Interv Imaging. 2018;99:163–168.CrossRefPubMed
25.
go back to reference Hickey R, Mouli S, Kulik L, et al. Independent analysis of albumin–bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2016;27:795–802.CrossRefPubMed Hickey R, Mouli S, Kulik L, et al. Independent analysis of albumin–bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2016;27:795–802.CrossRefPubMed
26.
go back to reference Chedid MF, Picon RV, Chedid AD. ALBI and PALBI: novel scores for outcome prediction of cirrhotic outpatients awaiting liver transplantation. Ann Hepatol. 2018;17:906–907.CrossRefPubMed Chedid MF, Picon RV, Chedid AD. ALBI and PALBI: novel scores for outcome prediction of cirrhotic outpatients awaiting liver transplantation. Ann Hepatol. 2018;17:906–907.CrossRefPubMed
27.
go back to reference Chan AW, Kumada T, Toyoda H, et al. Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1300–1306.CrossRefPubMed Chan AW, Kumada T, Toyoda H, et al. Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1300–1306.CrossRefPubMed
28.
go back to reference Cholankeril G, Wong RJ, Hu M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017;62:2915–2922.CrossRefPubMed Cholankeril G, Wong RJ, Hu M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017;62:2915–2922.CrossRefPubMed
Metadata
Title
Pre-transplant ALBI Grade 3 Is Associated with Increased Mortality After Liver Transplantation
Authors
Nicole Bernardi
Marcio F. Chedid
Tomaz J. M. Grezzana-Filho
Aljamir D. Chedid
Marcelo A. Pinto
Ian Leipnitz
João E. Prediger
Carolina Prediger
Ariane N. Backes
Thais O. Hammes
Lea T. Guerra
Alexandre de Araujo
Mario R. Alvares-da-Silva
Cleber R. P. Kruel
Publication date
01-06-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-5456-6

Other articles of this Issue 6/2019

Digestive Diseases and Sciences 6/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.